Movement Alert｜Revolution Medicines, Inc. Rises 5.23% in Regular Trading, FDA NDA Acceptance and Pre-Earnings Optimism Drive Multi-Catalyst Rally

Market Focus08-05 00:35

On August 5, Revolution Medicines, Inc. rose 5.23% in regular trading, trading near $191.85/share, with turnover of approximately $105 million.

On the news front, multiple catalysts converged to drive the stock higher. The FDA previously formally accepted the company's New Drug Application (NDA) for its core pipeline drug Daraxonrasib for the treatment of previously treated metastatic pancreatic cancer, marking a key regulatory milestone. Concurrently, the European Medicines Agency initiated a phased review to accelerate evaluation of the same drug. Wedbush raised its price target to $192.10 from $181, maintaining an Outperform rating, while the analyst consensus target stands at $203.85.

Additionally, the company is scheduled to report quarterly earnings after market close, with consensus expecting an EPS loss of $-1.93. Market expectations for the commercial prospects of its RAS-targeted therapies continue to build, particularly after Phase 3 data showed Daraxonrasib doubled median overall survival to 13.2 months versus 6.7 months for chemotherapy in metastatic pancreatic cancer patients.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100087933?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 00:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100087933","market":"us","top_or_hot":-1,"title":"Movement Alert｜Revolution Medicines, Inc. Rises 5.23% in Regular Trading, FDA NDA Acceptance and Pre-Earnings Optimism Drive Multi-Catalyst Rally","media":"Market Focus","content":"<p><p>On August 5, Revolution Medicines, Inc. rose 5.23% in regular trading, trading near $191.85/share, with turnover of approximately $105 million.</p><p>On the news front, multiple catalysts converged to drive the stock higher. The FDA previously formally accepted the company's New Drug Application (NDA) for its core pipeline drug Daraxonrasib for the treatment of previously treated metastatic pancreatic cancer, marking a key regulatory milestone. Concurrently, the European Medicines Agency initiated a phased review to accelerate evaluation of the same drug. Wedbush raised its price target to $192.10 from $181, maintaining an Outperform rating, while the analyst consensus target stands at $203.85.</p><p>Additionally, the company is scheduled to report quarterly earnings after market close, with consensus expecting an EPS loss of $-1.93. Market expectations for the commercial prospects of its RAS-targeted therapies continue to build, particularly after Phase 3 data showed Daraxonrasib doubled median overall survival to 13.2 months versus 6.7 months for chemotherapy in metastatic pancreatic cancer patients.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Revolution Medicines, Inc. Rises 5.23% in Regular Trading, FDA NDA Acceptance and Pre-Earnings Optimism Drive Multi-Catalyst Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Revolution Medicines, Inc. Rises 5.23% in Regular Trading, FDA NDA Acceptance and Pre-Earnings Optimism Drive Multi-Catalyst Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-05 00:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 5, Revolution Medicines, Inc. rose 5.23% in regular trading, trading near $191.85/share, with turnover of approximately $105 million.</p><p>On the news front, multiple catalysts converged to drive the stock higher. The FDA previously formally accepted the company's New Drug Application (NDA) for its core pipeline drug Daraxonrasib for the treatment of previously treated metastatic pancreatic cancer, marking a key regulatory milestone. Concurrently, the European Medicines Agency initiated a phased review to accelerate evaluation of the same drug. Wedbush raised its price target to $192.10 from $181, maintaining an Outperform rating, while the analyst consensus target stands at $203.85.</p><p>Additionally, the company is scheduled to report quarterly earnings after market close, with consensus expecting an EPS loss of $-1.93. Market expectations for the commercial prospects of its RAS-targeted therapies continue to build, particularly after Phase 3 data showed Daraxonrasib doubled median overall survival to 13.2 months versus 6.7 months for chemotherapy in metastatic pancreatic cancer patients.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"","article_id":"1100087933","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100087933","pubTimestamp":1785861339,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 5, Revolution Medicines, Inc. rose 5.23% in regular trading, trading near $191.85/share, with turnover of approximately $105 million.On the news front, multiple catalysts converged to drive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc."},"translate_title":"走势警报|Revolution Medicines, Inc. 常规交易中上涨 5.23%，FDA NDA 受理和财报前乐观情绪推动多重催化剂反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1},"content_text":"On August 5, Revolution Medicines, Inc. rose 5.23% in regular trading, trading near $191.85/share, with turnover of approximately $105 million.On the news front, multiple catalysts converged to drive the stock higher. The FDA previously formally accepted the company's New Drug Application (NDA) for its core pipeline drug Daraxonrasib for the treatment of previously treated metastatic pancreatic cancer, marking a key regulatory milestone. Concurrently, the European Medicines Agency initiated a phased review to accelerate evaluation of the same drug. Wedbush raised its price target to $192.10 from $181, maintaining an Outperform rating, while the analyst consensus target stands at $203.85.Additionally, the company is scheduled to report quarterly earnings after market close, with consensus expecting an EPS loss of $-1.93. Market expectations for the commercial prospects of its RAS-targeted therapies continue to build, particularly after Phase 3 data showed Daraxonrasib doubled median overall survival to 13.2 months versus 6.7 months for chemotherapy in metastatic pancreatic cancer patients.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100087933","isCrawlerRequest":true}